NEW YORK, May 18, 2023 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed’s oral delivery technology as well as insights from the Company’s recent Phase 3 oral insulin clinical trials.
Novel Therapies for Type 2 Diabetes & Obesity Summit
Date: Wednesday, May 31, 2023
Time: 1:30 p.m. E.T.
Location: Hyatt Regency Boston, Boston, MA
For more information regarding the summit and the presentation, please visit the Summit’s website: Home – Novel Therapies for Type 2 Diabetes & Obesity Summit 2023 (t2d-obesity-summit.com)
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. The Company’s novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed has offices in the United States and Israel. For more information, please visit www.oramed.com.
Company Contact:Zach Herschfus+1-844-9-ORAMED
Logo – https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oramed-to-present-at-novel-therapies-for-type-2-diabetes–obesity-summit-301828322.html
SOURCE Oramed Pharmaceuticals Inc.